Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Am J Kidney Dis. 2012 Aug 22;61(1):44–56. doi: 10.1053/j.ajkd.2012.07.014

Figure 3.

Figure 3

Subgroup meta-regression analyses examining the association of total-study-period ESA dose (per epoetin alfa–equivalent 10,000-U/wk increment) with all-cause mortality. The incidence rate ratio (IRR) and 95% confidence interval (CI) is displayed on a logarithmic scale. Here, “erythropoietin” refers to epoetin (alfa or beta); “darbepoetin” refers to darbepoetin alfa.